Payment overview · 2025
General Payments
$178.60
9 reported records · 7 companies
Healthcare provider profile · identity verified
Brian Davault, MD
Allopathic & Osteopathic Physicians|Family Medicine · WABASH, IN · NPI 1467946368
Verified facts
What the public records show
CMS Open Payments records show Brian Davault, MD received $178.60 in general payments during 2025 across 9 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 29.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.68 | 29.5% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $29.49 | 16.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.73 | 13.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.92 | 11.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.54 | 11.5% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.67 | 8.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.57 | 8.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $140.90 | 7 |
| Education | $37.70 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $52.68 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $29.49 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.73 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 101 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
101 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 570 | 173 |
| Levothyroxine Sodium | Levothyroxine Sodium | 554 | 142 |
| Atorvastatin Calcium | Atorvastatin Calcium | 438 | 139 |
| Lisinopril | Lisinopril | 343 | 98 |
| Losartan Potassium | Losartan Potassium | 281 | 86 |
| Omeprazole | Omeprazole | 263 | 85 |
| Gabapentin | Gabapentin | 233 | 56 |
| Carvedilol | Carvedilol | 196 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 189 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 185 | 63 |
| Metformin Hcl Er | Metformin Hcl | 185 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 168 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 167 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 45 |
| Metformin Hcl | Metformin Hcl | 158 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 143 | 45 |
| Simvastatin | Simvastatin | 140 | 37 |
| Trazodone Hcl | Trazodone Hcl | 138 | 35 |
| Montelukast Sodium | Montelukast Sodium | 136 | 34 |
| Sertraline Hcl | Sertraline Hcl | 131 | 40 |
| Famotidine | Famotidine | 123 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 108 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 27 |
| Meloxicam | Meloxicam | 102 | 31 |
| Jardiance | Empagliflozin | 101 | 19 |
| Furosemide | Furosemide | 100 | 38 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 99 | 28 |
| Eliquis | Apixaban | 94 | 26 |
| Glimepiride | Glimepiride | 86 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 29 |
| Allopurinol | Allopurinol | 83 | 24 |
| Bupropion Xl | Bupropion Hcl | 80 | 25 |
| Ozempic | Semaglutide | 80 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 25 |
| Buspirone Hcl | Buspirone Hcl | 76 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 23 |
| Spironolactone | Spironolactone | 68 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 17 |
| Chlorthalidone | Chlorthalidone | 67 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 19 |
| Glipizide Er | Glipizide | 60 | 17 |
| Topiramate | Topiramate | 54 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 13 |
| Ezetimibe | Ezetimibe | 53 | 19 |
| Celecoxib | Celecoxib | 48 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 12 |
| Potassium Chloride | Potassium Chloride | 46 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 14 |
| Alendronate Sodium | Alendronate Sodium | 44 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 13 |
| Synthroid | Levothyroxine Sodium | 42 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | suppressed |
| Pregabalin | Pregabalin | 38 | 12 |
| Atenolol | Atenolol | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 11 |
| Tramadol Hcl | Tramadol Hcl | 32 | 13 |
| Clonazepam | Clonazepam | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Prednisone | Prednisone | 23 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 19 |
| Finasteride | Finasteride | 22 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 11 |
| Repaglinide | Repaglinide | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Bystolic | Nebivolol Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $178.60 · 9 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AREXVY, Cologuard Collection Kit, Dexcom G6 Transmitter, INSPIRE, JARDIANCE, Jornay PM, SHINGRIX, Veozah | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error